Patents by Inventor Philip V. Felice

Philip V. Felice has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230201147
    Abstract: A natural water soluble protocatechuic acid and L-theanine cocrystal composition is described. The cocrystal composition may be created by a method including solvent-assisted mechanical grinding. The natural water soluble cocrystal composition is suitable for sublingual administration, preferably to humans.
    Type: Application
    Filed: October 28, 2022
    Publication date: June 29, 2023
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Philip V. FELICE, Harry G. BRITTAIN
  • Publication number: 20230201152
    Abstract: A natural water soluble protocatechuic acid and L-theanine cocrystal composition is described. The cocrystal composition may be created by a method including solvent-assisted mechanical grinding. The natural water soluble cocrystal composition is suitable for sublingual administration, preferably to humans.
    Type: Application
    Filed: October 28, 2022
    Publication date: June 29, 2023
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Philip V. FELICE, Harry G. BRITTAIN
  • Publication number: 20230149427
    Abstract: Compositions comprising cocrystals of acetylsalicylic acid and theanine that have been formulated with tromethamine are provided. Methods of preparing the compositions and methods of using the compositions with optional zinc or dipyridamole treatments are also provided.
    Type: Application
    Filed: December 8, 2022
    Publication date: May 18, 2023
    Inventors: Philip V. FELICE, Harry G. BRITTAIN, Paul WABNITZ
  • Publication number: 20230111210
    Abstract: A natural water soluble protocatechuic acid and L-theanine cocrystal composition is described. The cocrystal composition may be created by a method including solvent-assisted mechanical grinding. The natural water soluble cocrystal composition is suitable for sublingual administration, preferably to humans.
    Type: Application
    Filed: October 28, 2022
    Publication date: April 13, 2023
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Philip V. FELICE, Harry G. BRITTAIN
  • Publication number: 20230110872
    Abstract: A water-soluble aspirin, citric acid, sodium bicarbonate, L-theanine cocrystal composition which includes a quantity of acetylsalicylic acid is described. The composition may be created by a method including various steps, including a cocrystallization step. The water-soluble cocrystal composition is suitable for sublingual administration, preferably to humans.
    Type: Application
    Filed: December 12, 2022
    Publication date: April 13, 2023
    Applicant: THEAPRIN PHARMACEUTICALS, INC.
    Inventors: Philip V. FELICE, Harry G. BRITTAIN
  • Publication number: 20230115710
    Abstract: A water-soluble aspirin, citric acid, sodium bicarbonate, L-theanine cocrystal composition which includes a quantity of acetylsalicylic acid is described. The composition may be created by a method including various steps, including a cocrystallization step. The water-soluble cocrystal composition is suitable for sublingual administration, preferably to humans.
    Type: Application
    Filed: December 12, 2022
    Publication date: April 13, 2023
    Applicant: THEAPRIN PHARMACEUTICALS, INC.
    Inventors: Philip V. FELICE, Harry G. BRITTAIN
  • Publication number: 20210177758
    Abstract: A platform drug delivery system and a method of improving the delivery of low solubility pharmaceuticals utilizing crystal engineering and Theanine dissolution resulting in enhanced bioactivity, dissolution rate, and solid state stability.
    Type: Application
    Filed: February 24, 2021
    Publication date: June 17, 2021
    Applicant: THEAPRIN PHARMACEUTICALS, INC.
    Inventors: Harry G. BRITTAIN, Philip V. FELICE
  • Publication number: 20200101010
    Abstract: A water-soluble aspirin, citric acid, sodium bicarbonate, L-theanine cocrystal composition which includes a quantity of acetylsalicylic acid is described. The composition may be created by a method including various steps, including a cocrystallization step. The water-soluble cocrystal composition is suitable for sublingual administration, preferably to humans.
    Type: Application
    Filed: May 30, 2018
    Publication date: April 2, 2020
    Applicant: THEAPRIN PHARMACEUTICALS, INC.
    Inventors: Philip V. FELICE, Harry G. BRITTAIN
  • Patent number: 10376464
    Abstract: Cocrystal compositions of metoprolol and dabigatran bases with enantiomers of theanine.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: August 13, 2019
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Publication number: 20180064649
    Abstract: A platform drug delivery system and a method of improving the delivery of low solubility pharmaceuticals utilizing crystal engineering and Theanine dissolution resulting in enhanced bioactivity, dissolution rate, and solid state stability.
    Type: Application
    Filed: February 29, 2016
    Publication date: March 8, 2018
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. BRITTAIN, Philip V. FELICE
  • Patent number: 9896411
    Abstract: Methods of making cocrystal compositions of metoprolol and dabigatran bases with enantiomers of theanine.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: February 20, 2018
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Publication number: 20170143648
    Abstract: Methods of treating and preventing conditions by employing cocrystal compositions of metoprolol and dabigatran bases with enantiomers of theanine.
    Type: Application
    Filed: November 17, 2016
    Publication date: May 25, 2017
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Publication number: 20170144964
    Abstract: Methods of making cocrystal compositions of metoprolol and dabigatran bases with enantiomers of theanine.
    Type: Application
    Filed: November 17, 2016
    Publication date: May 25, 2017
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Publication number: 20170143838
    Abstract: Cocrystal compositions of metoprolol and dabigatran bases with enantiomers of theanine.
    Type: Application
    Filed: October 3, 2016
    Publication date: May 25, 2017
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: HARRY G. BRITTAIN, Philip V. Felice
  • Patent number: 9603937
    Abstract: A platform drug delivery system and a method of improving the delivery of low solubility pharmaceuticals utilizing crystal engineering and Theanine dissolution resulting in enhanced bioactivity, dissolution rate, and solid state stability.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: March 28, 2017
    Assignee: Theaprin Pharmaceuticals Inc.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Patent number: 9603939
    Abstract: A method of treating Hodgkin's disease in a subject. The method involves administering to the subject an effective amount of a water-soluble composition which includes a cocrystal composition containing doxorubicin and a theanine enantiomer.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: March 28, 2017
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Patent number: 9603938
    Abstract: A method of making a water-soluble doxorubicin-theanine cocrystal composition. The method includes the steps of providing a quantity of doxorubicin, adding a quantity of a theanine enantiomer to the quantity of doxorubicin to form a mixture of the quantity of doxorubicin and the enantiomer of theanine, wetting the mixture, and grinding the mixture for a length of time sufficient to produce a dried crystalline mass.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: March 28, 2017
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Publication number: 20160263138
    Abstract: A method of treating Hodgkin's disease in a subject. The method involves administering to the subject an effective amount of a water-soluble composition which includes a cocrystal composition containing doxorubicin and a theanine enantiomer.
    Type: Application
    Filed: April 13, 2016
    Publication date: September 15, 2016
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: HARRY G. BRITTAIN, Philip V. Felice
  • Publication number: 20160263229
    Abstract: A method of making a water-soluble doxorubicin-theanine cocrystal composition. The method includes the steps of providing a quantity of doxorubicin, adding a quantity of a theanine enantiomer to the quantity of doxorubicin to form a mixture of the quantity of doxorubicin and the enantiomer of theanine, wetting the mixture, and grinding the mixture for a length of time sufficient to produce a dried crystalline mass.
    Type: Application
    Filed: March 24, 2016
    Publication date: September 15, 2016
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: HARRY G. BRITTAIN, Philip V. Felice
  • Publication number: 20160263224
    Abstract: A platform drug delivery system and a method of improving the delivery of low solubility pharmaceuticals utilizing crystal engineering and Theanine dissolution resulting in enhanced bioactivity, dissolution rate, and solid state stability.
    Type: Application
    Filed: March 9, 2015
    Publication date: September 15, 2016
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice